Jazz Pharmaceuticals (JAZZ) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $5.71
- Estimate
- $6.18
- Surprise
- -7.5%
- Revenue (period 2026-06-30)
- $1.21B
- Score at report (before → after)
- 6.3 → 6.3/10
Revenue source: xbrl.
How the report landed
Jazz Pharmaceuticals (JAZZ) missed the $6.18 estimate with adjusted EPS of $5.71 — a clear 7.5% shortfall. TrendMatrix's engine moved from Buy (Wait) (6.3/10) to Hold at 6.3/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates JAZZ Buy (Wait) at 6.7/10.
3 of the last 4 quarters beat the estimate; this quarter's -7.5% surprise compares with a +17.4% four-quarter average. Next scheduled report: 2026-11-02.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.2 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Supplier: ESSDS
- Earnings in 4 days (event risk)
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $209.12
- Entry target
- $204.36
- Price target
- $265.83
- Stop
- $196.23
- Upside to target
- +27.1%
- Reward-to-risk
- 4.8:1
The stock trades at 14.1× trailing but 7.9× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
JAZZ at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $13.31B
- P/E (fwd)
- 7.9
- P/E (ttm)
- 14.1
- 52-week range
- $128.80–$266.38
- Off 52-week high
- 21.5%
- RSI (14)
- 40
- Volume vs avg
- 0.17×
- Score today
- 6.7/10